ID

30259

Descripción

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00527735

Link

https://clinicaltrials.gov/show/NCT00527735

Palabras clave

Versiones (1)
  1. 25/5/18 25/5/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

25 de mayo de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Lung Cancer NCT00527735

Inglés

Eligibility Lung Cancer NCT00527735

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed lung cancer (stage iiib/iv nonsmall-cell lung cancer or extensive stage small-cell lung cancer [sclc])
Descripción

Carcinoma of lung | Non-Small Cell Lung Carcinoma TNM clinical staging | Small cell lung cancer extensive stage

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0684249
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C3258246
UMLS CUI [3]
C0278726
measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified world health organization criteria
Descripción

Measurable Disease | Exception Irradiation Area Previous

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1522449
UMLS CUI [2,3]
C0005902
UMLS CUI [2,4]
C0205156
eastern cooperative oncology group performance status of ≤1 at study entry
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
accessible for treatment and follow-up
Descripción

Accessibility Therapeutic procedure | Accessibility Follow-up

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0814423
UMLS CUI [1,2]
C0087111
UMLS CUI [2,1]
C0814423
UMLS CUI [2,2]
C3274571
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
brain metastases
Descripción

Metastatic malignant neoplasm to brain

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
malignant pleural effusion
Descripción

Pleural Effusion, Malignant

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0080032
autoimmune disease
Descripción

Autoimmune Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004364
motor neuropathy of autoimmune origin
Descripción

Motor neuropathy Origin Autoimmune process

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0235025
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C0443146
sclc-related paraneoplastic syndromes
Descripción

Paraneoplastic Syndromes Relationship Small cell carcinoma of lung

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030472
UMLS CUI [1,2]
C0439849
UMLS CUI [1,3]
C0149925
any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)
Descripción

Cancer Other | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of female breast | Exception Systemic therapy Prostate carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0686288
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1515119
UMLS CUI [5,3]
C0600139
prior systemic therapy for lung cancer. prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.
Descripción

Systemic therapy Carcinoma of lung | Prior radiation therapy allowed | Operative Surgical Procedures Locoregional Previous allowed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0684249
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C0683607
UMLS CUI [3,1]
C0543467
UMLS CUI [3,2]
C1947913
UMLS CUI [3,3]
C0205156
UMLS CUI [3,4]
C0683607
grade 2 peripheral neuropathy (motor or sensory)
Descripción

Peripheral motor neuropathy CTCAE Grades | Sensory neuropathy CTCAE Grades

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0235025
UMLS CUI [1,2]
C1516728
UMLS CUI [2,1]
C0151313
UMLS CUI [2,2]
C1516728
known hiv or hepatitis b or c infection
Descripción

HIV Infection | Hepatitis B | Hepatitis C

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). however, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.
Descripción

Immunosuppressive Agents chronic | CORTICOSTEROIDS FOR SYSTEMIC USE | Exception Paclitaxel Infusion | Exception Adverse event Relationship Immune system | Exception Adrenal Insufficiency Adverse Event

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2]
C3653708
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0144576
UMLS CUI [3,3]
C0574032
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0877248
UMLS CUI [4,3]
C0439849
UMLS CUI [4,4]
C0020962
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1963059
inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dl.
Descripción

Hematologic function Inadequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0518015
inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (uln), or ≥2.5 times the uln if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the uln or
Descripción

Liver function Inadequate | Elevated total bilirubin | Relationship Secondary malignant neoplasm of liver | Aspartate aminotransferase increased | Alanine aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0741494
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0494165
UMLS CUI [4]
C0151904
UMLS CUI [5]
C0151905
≥5 times the uln if liver metastases are present.
Descripción

Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151904
UMLS CUI [2]
C0151905
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0494165
inadequate renal function defined by a serum creatinine level ≥2.5 times the uln
Descripción

Renal function Inadequate | Serum creatinine raised

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0700225
inadequate creatinine clearance defined as less than 50 ml/min.
Descripción

Creatinine clearance Inadequate

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0812399
UMLS CUI [1,2]
C0205412
Volver a la parte superior de la página

Similar models

Eligibility Lung Cancer NCT00527735

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Carcinoma of lung | Non-Small Cell Lung Carcinoma TNM clinical staging | Small cell lung cancer extensive stage
Item
histologically or cytologically confirmed lung cancer (stage iiib/iv nonsmall-cell lung cancer or extensive stage small-cell lung cancer [sclc])
boolean
C0684249 (UMLS CUI [1])
C0007131 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0278726 (UMLS CUI [3])
Measurable Disease | Exception Irradiation Area Previous
Item
measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified world health organization criteria
boolean
C1513041 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0005902 (UMLS CUI [2,3])
C0205156 (UMLS CUI [2,4])
ECOG performance status
Item
eastern cooperative oncology group performance status of ≤1 at study entry
boolean
C1520224 (UMLS CUI [1])
Accessibility Therapeutic procedure | Accessibility Follow-up
Item
accessible for treatment and follow-up
boolean
C0814423 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0814423 (UMLS CUI [2,1])
C3274571 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain
Item
brain metastases
boolean
C0220650 (UMLS CUI [1])
Pleural Effusion, Malignant
Item
malignant pleural effusion
boolean
C0080032 (UMLS CUI [1])
Autoimmune Disease
Item
autoimmune disease
boolean
C0004364 (UMLS CUI [1])
Motor neuropathy Origin Autoimmune process
Item
motor neuropathy of autoimmune origin
boolean
C0235025 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C0443146 (UMLS CUI [1,3])
Paraneoplastic Syndromes Relationship Small cell carcinoma of lung
Item
sclc-related paraneoplastic syndromes
boolean
C0030472 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0149925 (UMLS CUI [1,3])
Cancer Other | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of female breast | Exception Systemic therapy Prostate carcinoma
Item
any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0686288 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1515119 (UMLS CUI [5,2])
C0600139 (UMLS CUI [5,3])
Systemic therapy Carcinoma of lung | Prior radiation therapy allowed | Operative Surgical Procedures Locoregional Previous allowed
Item
prior systemic therapy for lung cancer. prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.
boolean
C1515119 (UMLS CUI [1,1])
C0684249 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0543467 (UMLS CUI [3,1])
C1947913 (UMLS CUI [3,2])
C0205156 (UMLS CUI [3,3])
C0683607 (UMLS CUI [3,4])
Peripheral motor neuropathy CTCAE Grades | Sensory neuropathy CTCAE Grades
Item
grade 2 peripheral neuropathy (motor or sensory)
boolean
C0235025 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0151313 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
HIV Infection | Hepatitis B | Hepatitis C
Item
known hiv or hepatitis b or c infection
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Immunosuppressive Agents chronic | CORTICOSTEROIDS FOR SYSTEMIC USE | Exception Paclitaxel Infusion | Exception Adverse event Relationship Immune system | Exception Adrenal Insufficiency Adverse Event
Item
chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). however, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C3653708 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0144576 (UMLS CUI [3,2])
C0574032 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0877248 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C0020962 (UMLS CUI [4,4])
C1705847 (UMLS CUI [5,1])
C1963059 (UMLS CUI [5,2])
Hematologic function Inadequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement
Item
inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dl.
boolean
C0221130 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
Liver function Inadequate | Elevated total bilirubin | Relationship Secondary malignant neoplasm of liver | Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (uln), or ≥2.5 times the uln if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the uln or
boolean
C0232741 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0741494 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C0494165 (UMLS CUI [3,2])
C0151904 (UMLS CUI [4])
C0151905 (UMLS CUI [5])
Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver
Item
≥5 times the uln if liver metastases are present.
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C0494165 (UMLS CUI [3,2])
Renal function Inadequate | Serum creatinine raised
Item
inadequate renal function defined by a serum creatinine level ≥2.5 times the uln
boolean
C0232804 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0700225 (UMLS CUI [2])
Creatinine clearance Inadequate
Item
inadequate creatinine clearance defined as less than 50 ml/min.
boolean
C0812399 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial